Related Experiment Video
Updated: Aug 19, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Gefitinib in advanced non-small cell lung cancer
Background:
Gefitinib is an oral, selective epidermal growth factor receptor (EGFR) inhibitor that has activity in non-small cell lung cancer (NSCLC).
Aim:
To evaluate the tolerability, safety-profile and response of single agent gefitinib in patients with advanced stage NSCLC.
Methods:
Twenty-seven patients of good performance status with stage IIIB or IV NSCLC were entered on the study at the Sydney Cancer Centre. Gefitinib was prescribed at an oral dose of 250 mg daily, as a continuous dose. Radiological evaluation of indicator lesions occurred at baseline and were repeated every 2-3 months until disease progression. Toxicity was graded using standard measures at baseline and at every month.
Results:
The response rate was 17% in the patients eligible for evaluation. Symptom improvement was observed in 75% of patients. No patients withdrew because of adverse events. Toxicity was observed in 15 patients and consisted mainly of rash (59%), which was usually mild in severity.
Conclusion:
Gefitinib is active in NSCLC. It is well tolerated with minimal side-effects. Symptomatic improvement was found in the majority of patients treated with gefitinib. There may be a role for gefitinib in the palliation of symptoms in patients with advanced NSCLC.
Insights
Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, showed activity in non-small cell lung cancer (NSCLC). It was well-tolerated, with most patients experiencing symptom improvement and mild rash as the main side effect.
Area of Science:
- Oncology
- Pharmacology
Background:
- Gefitinib is an oral, selective epidermal growth factor receptor (EGFR) inhibitor.
- It demonstrates activity in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To assess the tolerability and safety of single-agent gefitinib.
- To evaluate the response rate of gefitinib in advanced NSCLC patients.
Main Methods:
- A study involving 27 patients with stage IIIB or IV NSCLC.
- Gefitinib was administered orally at 250 mg daily.
- Radiological and toxicity evaluations were conducted regularly.
Main Results:
- A 17% response rate was observed in evaluable patients.
- Symptom improvement occurred in 75% of patients.
- Rash was the most common toxicity, typically mild.
Conclusions:
- Gefitinib is an active treatment for NSCLC.
- The drug is well-tolerated with minimal adverse events.
- Gefitinib may be beneficial for symptom palliation in advanced NSCLC.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
